Drug intelligence / Profile preview

Feminabiane CU

Development stage: Unknown
Lead developer: PiLeJe
Administration: Oral

Overview

Feminabiane CU is a Spanish dietary supplement marketed for urinary tract symptoms. It has been implicated in a case of acute interstitial nephritis (AIN) and electrolyte derangements, including severe symptomatic hyponatremia, rising creatinine, and transaminitis, highlighting the diagnostic challenges posed by poorly regulated supplements with complex ingredient profiles.

Brand names: Feminabiane CU Flash

Beyond the preview

Go deeper on Feminabiane CU.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Feminabiane CU.

Explore the full profile